United States pharmaceutical maker, Pfizer, and biopharmaceutical company, Global Blood Therapeutics (GBT), on Monday, agreed that Pfizer would acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars.
Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
According to dpa, under the terms of the transaction, Pfizer will acquire all the outstanding shares of California-based GBT for 68.50 dollars per share in cash, for a total enterprise value of approximately 5.4 billion dollars, including debt and net of cash acquired.
READ ALSO: BioNTech, Pfizer to develop vaccine against shingles
The pharmaceutical company expects to finance the transaction with existing cash on hand.
The proposed transaction, unanimously approved by the Boards of Directors of both companies, is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT’s stockholders.
The Council of Otunbas in Ijebuland has declared that no law prohibits holders of the…
The Kebbi State Police Command has arrested a man, Hamza Sama, for allegedly running a…
Kaduna State Governor, Uba Sani, has announced plans to construct what he described as the…
Manchester United climbed into fourth place in the Premier League after edging leaders Arsenal in…
Oyo State Governor, Seyi Makinde, has criticised the administration of President Bola Tinubu, saying it…
President Bola Tinubu will depart Abuja on Monday, January 26, 2026, for a state visit…
This website uses cookies.